TY - JOUR
T1 - Early detection of cognitive decline in mild cognitive impairment and Alzheimer's disease with a novel eye tracking test
AU - Tadokoro, Koh
AU - Yamashita, Toru
AU - Fukui, Yusuke
AU - Nomura, Emi
AU - Ohta, Yasuyuki
AU - Ueno, Setsuko
AU - Nishina, Saya
AU - Tsunoda, Keiichiro
AU - Wakutani, Yosuke
AU - Takao, Yoshiki
AU - Miyoshi, Takahiro
AU - Higashi, Yasuto
AU - Osakada, Yosuke
AU - Sasaki, Ryo
AU - Matsumoto, Namiko
AU - Kawahara, Yuko
AU - Omote, Yosio
AU - Takemoto, Mami
AU - Hishikawa, Nozomi
AU - Morihara, Ryuta
AU - Abe, Koji
N1 - Funding Information:
We are grateful to Ms. Kadota, Ms. Kanao, and Ms. Otsuka for their technical assistance. This work was partly supported by a Grant-in-Aid for Scientific Research [grant numbers (B) 17H0419611 , (C) 15K0931607 , 17H0975609 , and 17K1082709 ], and by Grants-in-Aid from the Research Committees (Kaji R, Toba K, and Tsuji S) from the Japan Agency for Medical Research and Development [grant numbers 7211800049 , 7211800130 , and 7211700121 ].
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8/15
Y1 - 2021/8/15
N2 - Due to an increasing number of dementia patients, the development of a rapid and sensitive method for cognitive assessment is awaited. Here, we examined the usefulness of a novel and short (3 min) eye tracking device to evaluate the cognitive function of normal control (NC, n = 52), mild cognitive impairment (MCI, n = 52), and Alzheimer's disease (AD, n = 70) subjects. Eye tracking total score declined significantly in MCI (**p < 0.01 vs NC) and AD (**p < 0.01 vs NC, ##p < 0.01 vs MCI), and correlated well with the mini-mental state examination (MMSE) score (r = 0.57, *p < 0.05). Furthermore, the eye tracking test, especially memory and deductive reasoning tasks, effectively discriminated NC, MCI and AD. The present novel eye tracking test clearly discriminated cognitive functions among NC, MCI, and AD subjects, thereby providing an advantage for the early detection of MCI and AD in screening.
AB - Due to an increasing number of dementia patients, the development of a rapid and sensitive method for cognitive assessment is awaited. Here, we examined the usefulness of a novel and short (3 min) eye tracking device to evaluate the cognitive function of normal control (NC, n = 52), mild cognitive impairment (MCI, n = 52), and Alzheimer's disease (AD, n = 70) subjects. Eye tracking total score declined significantly in MCI (**p < 0.01 vs NC) and AD (**p < 0.01 vs NC, ##p < 0.01 vs MCI), and correlated well with the mini-mental state examination (MMSE) score (r = 0.57, *p < 0.05). Furthermore, the eye tracking test, especially memory and deductive reasoning tasks, effectively discriminated NC, MCI and AD. The present novel eye tracking test clearly discriminated cognitive functions among NC, MCI, and AD subjects, thereby providing an advantage for the early detection of MCI and AD in screening.
KW - Alzheimer's disease
KW - Cognitive assessment
KW - Eye tracking technology
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85107745700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107745700&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2021.117529
DO - 10.1016/j.jns.2021.117529
M3 - Article
C2 - 34130064
AN - SCOPUS:85107745700
SN - 0022-510X
VL - 427
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 117529
ER -